References
- Gavin A, Rous B, Marcos-Gragera R, Middleton R, Steliarova-Foucher E, Maynadie M, et al. Towards optimal clinical and epidemiological registration of haematological malignancies: Guidelines for recording progressions, transformations and multiple diagnoses. Eur J Cancer 2015;51:1109–22.
- Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al, editors. International Classification of Diseases for Oncology, 3rd edition (ICD-O-3). Geneva: World Health Organization; 2000.
- Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994;33:365–9.
- Lönnberg S, Leinonen M, Malila N, Anttila A. Validation of histological diagnoses in a national cervical screening register. Acta Oncol 2011;51:37–44.
- Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Geneva: World Health Organization, 2008.
- Sant M, Karjalainen-Lindsberg ML, Maynadié M, Raphaël M, Ferretti S, Giacomin A, editors, et al. Manual for coding and reporting haematological malignancies. Tumori 2010;96.4:i.
- Sund R. Quality of the Finnish Hospital Discharge Register: a systematic review. Scand J Public Health 2012;40:505–15.
- Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, et al., editors (2013). Cancer Incidence in Five Continents, Vol. X (electronic version). Lyon: International Agency for Research on Cancer. Available from: http://ci5.iarc.fr.
- Aasbrenn M, Langmark F, Wisløff F. Is registration of multiple myeloma in the Norwegian Cancer Registry good enough? Tidsskr nor Laegeforen 2008;128:2712–4. [Norwegian]
- Larsen IK, Småstuen M, Johannesen TB, Langmark F, Parkin DM, Bray F. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009;45:1218–31.
- Nørgaard M, Skriver MV, Gregersen H, Pedersen G, Schønheyder HC, Sørensen HT. The data quality of haematological malignancy ICD-10 diagnoses in a population-based hospital discharge registry. Eur J Cancer Prev 2005;14:201–6.
- Sigurdardottir LG, Jonasson JG, Stefansdottir S, Jonsdottir A, Olafsdottir GH, Olafsdottir EJ, et al. Data quality at the Icelandic Cancer Registry: comparability, validity, timeliness and completeness. Acta Oncol 2012;51:880–9.
- Shi J, Shao ZH, Liu H, Bai J, Cao YR, He GS, et al. Transformation of myelodysplastic syndromes into acute myeloid leukemias. Chin Med J 2004;117:963–7.
- Björkholm M, Derolf AR, Hultcrantz M, Kristinsson SY, Ekstrand C, Goldin LR, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol 2011;29:2410–5.
- Okuyama N, Sperr WR, Kadar K, Bakker S, Szombath G, Handa H, et al. Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: a multicenter retrospective study. Leuk Res 2013;37:862–7.
- Phekoo K, Møller H, Richards M, Schey S. Comparison of a specialist haematological malignancy database against a regional cancer registry: case ascertainment and diagnostic accuracy. Br J Haematol 2002;119:697–705.
- Parkin DM, Bray F. Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness. Eur J Cancer 2009;45:756–64.